BHP Shares Fall as Jansen Potash Project Costs Surge 
DOJ Sues Virginia Over Law Enforcement Mask Ban 
Trump Administration Defends Anthropic AI Restrictions in Ongoing Federal Lawsuit 
SK Hynix Shares Hit Record High After Shipping Next-Generation HBM4E AI Memory Samples 
Trump Administration Delays DeepSeek and CXMT Trade Blacklist Designations Amid U.S.-China Tensions 
G7 Explores AI Access Deal With U.S. Amid Anthropic Restrictions 
Italy’s ITA Airways Weighs Legal Action Against Pratt & Whitney Over Grounded Airbus Fleet 
DOJ Sues UCLA Over Alleged Antisemitism and Hostile Campus Environment 
U.S. Supreme Court to Review Trump Administration Appeal on Immigrant Detention Without Bond Hearings 
Biden Sues DOJ to Block Release of Audio From Classified Documents Probe 
Obayashi to Acquire Multiplex in $526M Expansion Deal 
Brazil Supreme Court Convicts Eduardo Bolsonaro Over U.S. Lobbying Efforts 
SpaceX Stock Slides After IPO Rally as Valuation Concerns Grow 
Carro Expands Into Australia With Acquisition of Used-Car Platform CarPlace 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
Trump Team Rejects BBC Financial Data Request in $10B Lawsuit 
Saudi Aramco Explores Sulphur Business Stake Sale to Raise Billions 
Texas Attorney General Ken Paxton has filed a lawsuit against pharmaceutical giant Sanofi, accusing the company of unlawfully incentivizing healthcare providers to prescribe its medications instead of competing alternatives. According to the attorney general’s office, Sanofi allegedly created service-based programs for healthcare professionals that effectively functioned as bribes, in violation of the Texas Health Care Program Fraud Prevention Act.
State officials claim these programs were designed to improperly influence prescribing decisions, potentially impacting fair competition and patient care within Texas healthcare programs. The lawsuit seeks more than $1 million in monetary relief, including civil penalties, as well as a court injunction to prevent any further alleged unlawful conduct.
Sanofi has strongly denied the allegations. In a public statement, the company asserted that its services are fully structured to comply with both federal and state regulations. Sanofi emphasized that the programs are intended to support patient care and improve health outcomes, not to sway physicians’ prescribing behavior. The company also stated that the state’s legal action does not reflect the merits of the case and confirmed it will vigorously defend itself in court.
This is not the first time Attorney General Paxton has taken legal action against major pharmaceutical companies. Previously, Texas sued Sanofi and Bristol-Myers Squibb, alleging they failed to disclose that their blood thinner Plavix was less effective for certain patients. In a separate case last year, the state filed a lawsuit against Eli Lilly, accusing the drugmaker of bribing healthcare providers to prescribe its top-selling medications, including GLP-1 drugs Mounjaro and Zepbound.
The latest lawsuit highlights Texas’ continued scrutiny of pharmaceutical industry practices, particularly regarding alleged healthcare fraud, drug marketing tactics, and compliance with state healthcare laws.
